Novavax News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.12.22	MÄRKTE USA/Zins- und Rezessionsängste schicken Aktien auf Talfahrt (Dow Jones)
15.12.22	MÄRKTE USA/Zinsängste schicken Aktien auf Talfahrt (Dow Jones)
15.12.22	MÄRKTE USA/Weiter abwärts nach Fed-Aussagen (Dow Jones)
15.12.22	MÄRKTE USA/Weiter abwärts nach Fed-Aussagen - Tesla schwach erwartet (Dow Jones)
15.12.22	MARKT USA/Weiter abwärts nach Fed-Aussagen - Tesla schwach erwartet (Dow Jones)
14.12.22	Novavax Announces Proposed $125 Million Public Offering of Common Stock (PR Newswire)
14.12.22	Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes (PR Newswire)
07.12.22	Novavax : Canada Approves Nuvaxovid COVID-19 Vaccine For Use As Primary Series In Adolescents (RTTNews)
07.12.22	Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents (PR Newswire)
02.12.22	Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference (PR Newswire)
29.11.22	WHO Issues Updated Emergency Use Listing For Novavax's Nuvaxovid COVID-19 Vaccine (RTTNews)
29.11.22	World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults (PR Newswire)
18.11.22	Novavax: Health Canada Approves Nuvaxovid COVID-19 Vaccine As Adult Booster (RTTNews)
18.11.22	Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults (PR Newswire)
14.11.22	Novavax to Participate in Jefferies London Healthcare Conference (PR Newswire)
09.11.22	Novavax's Nuvaxovid COVID-19 Vaccine Authorized In U.K. For Use As Booster In Adults (RTTNews)
09.11.22	Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults (PR Newswire)
08.11.22	Novavax Inc. Q3 Loss decreases, but misses estimates (RTTNews)
08.11.22	Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights (PR Newswire)
08.11.22	Novavax BA.1 Vaccine Candidate Meets Primary Strain-change Endpoint (RTTNews)
08.11.22	Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster (PR Newswire)
07.11.22	Ausblick: Novavax vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
01.11.22	Novavax Appoints Rick Rodgers to Board of Directors (PR Newswire)
01.11.22	Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022 (PR Newswire)
20.10.22	Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022 (PR Newswire)
19.10.22	FDA Grants EUA For Novavax COVID-19 Vaccine, Adjuvanted As A Booster For Adults (RTTNews)
19.10.22	U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults (PR Newswire)
13.10.22	Novavax's CIC Vaccine Candidate Induces Antibody, T-Cell Responses Against SARS-CoV-2 (RTTNews)
13.10.22	Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains (PR Newswire)
12.10.22	Novavax: Prototype NVX-CoV2373 Achieves Pre-specified Immunologic Endpoint In PREVENT-19 Trial (RTTNews)
12.10.22	Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants (PR Newswire)
10.10.22	Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022 (PR Newswire)
27.09.22	Novavax Says One Mln Doses Of Nuvaxovid Ready For Use In UK To Fight Covid-19 (RTTNews)
27.09.22	Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom (PR Newswire)
21.09.22	Deutschland muss 4,6 Millionen Impfstoffdosen von Moderna und Novavax entsorgen - Aktien tiefer (Dow Jones) Die Bundesregierung muss immer mehr Corona-Impfstoff entsorgen.» mehr
16.09.22	Novavax's Nuvaxovid COVID-19 Vaccine Gets Expanded EUA In Taiwan For Use In Adolescents (RTTNews)
16.09.22	Novavax's Says Nuvaxovid COVID-19 Vaccine Now Available In Israel For Individuals Aged 12 And Older (RTTNews)
16.09.22	Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17 (PR Newswire)
16.09.22	Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older (PR Newswire)
13.09.22	Novavax Reports Full Product Registration In South Africa Of Novavax COVID-19 Vaccine (RTTNews)
13.09.22	Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older (PR Newswire)
12.09.22	Novavax Says Nuvaxovid Covid-19 Vaccine Gets Expanded CMA In EU As Booster; Stock Up (RTTNews)
12.09.22	Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older (PR Newswire)
07.09.22	Novavax to Participate in Upcoming September Conferences (PR Newswire)
03.09.22	Swissmedic Authorizes Novavax COVID-19 Vaccine For Adolescents And As Booster In Adults (RTTNews)
02.09.22	Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older (PR Newswire)
02.09.22	Novavax : CHMP Recommends Approval Of Its COVID-19 Booster Vaccine (RTTNews)
01.09.22	Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older (PR Newswire)
26.08.22	Novavax's COVID-19 Vaccine Granted Expanded Conditional Authorization In U.K. For Adolescents (RTTNews)
26.08.22	Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	237.10	1.80 %	K V
ABB	42.20	1.44 %	K V
Nestle	87.98	1.36 %	K V
Swiss Re	141.80	1.18 %	K V
CieFinRichemont	136.90	1.00 %	K V
Sika	195.55	-0.23 %	K V
Lonza Grp	539.20	-0.44 %	K V
Alcon	75.38	-0.48 %	K V
Holcim	87.62	-0.88 %	K V
Geberit	551.20	-1.29 %	K V

mehr

18.04.25		Bayer-Aktie: Bayer-Chef erwägt mögliches Aus für Glyphosat in den USA
18.04.25		DAX 40-Wert Bayer-Aktie: So viel Verlust hätte ein Bayer-Investment von vor 3 Jahren eingebracht
18.04.25		SMI-Wert Roche-Aktie: So viel Gewinn hätte eine Roche-Investition von vor einem Jahr eingebracht
17.04.25		Roche-Analyse: JP Morgan Chase & Co. bewertet Roche-Aktie mit Underweight in neuer Analyse
17.04.25		S&P 500-Titel Moderna-Aktie: So viel Verlust hätte ein Investment in Moderna von vor 3 Jahren bedeutet
16.04.25		Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Verlust hätte ein Johnson Johnson-Investment von vor 3 Jahren eingebracht
15.04.25		Johnson & Johnson steigert in Q1 Umsatz und Gewinn - Aktie leichter
15.04.25		S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr bedeutet

18.04.25

Bayer-Aktie: Bayer-Chef erwägt mögliches Aus für Glyphosat in den USA

18.04.25

DAX 40-Wert Bayer-Aktie: So viel Verlust hätte ein Bayer-Investment von vor 3 Jahren eingebracht

18.04.25

SMI-Wert Roche-Aktie: So viel Gewinn hätte eine Roche-Investition von vor einem Jahr eingebracht

17.04.25

Roche-Analyse: JP Morgan Chase & Co. bewertet Roche-Aktie mit Underweight in neuer Analyse

17.04.25

S&P 500-Titel Moderna-Aktie: So viel Verlust hätte ein Investment in Moderna von vor 3 Jahren bedeutet

16.04.25

Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Verlust hätte ein Johnson Johnson-Investment von vor 3 Jahren eingebracht